McNeil proposed aspirin claims "unsupported," Aspirin Foundation of America protests.
This article was originally published in The Tan Sheet
Executive Summary
McNEIL PROPOSED ASPIRIN LABEL WARNINGS "UNSUPPORTED," AFA CLAIMS in June 10 comments to FDA. The Aspirin Foundation of America objects to McNeil's recent proposal to FDA that aspirin labeling advise physician consultation for analgesic or antipyretic use when aspirin is being taken chronically for cardiovascular benefits. "The proposal, like other elements of McNeil's marketing campaign, is wholly unsupported by science and should be categorically dismissed," AFA maintains.